Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3870MR)

This product GTTS-WQ3870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7348MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ9142MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ10227MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ9652MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ6675MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ7485MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ11374MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ11041MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-128
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW